BLA 761142 · Viela Bio
Uplizna
Inebilizumab-Cdon · Injection · CD19-directed Cytolytic Antibody
NovelBreakthrough therapyOrphanLast checked: Nov 20, 2026Latest source record: Sep 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Jun 11, 2020
Approved uses
3
Original approval plus efficacy supplements
Registered trials
28
7 Phase 3, 11 recruiting
FAERS reports
858
625 serious, 53 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 21, 2026.
UPLIZNA is a CD19-directed cytolytic antibody indicated for the treatment of: Neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. ( 1.1 ) Immunoglobulin G4-related disease (IgG4-RD) in adult patients. ( 1.2 ) Generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive. ( 1.2 ) 1.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) UPLIZNA is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. 1.2 Immunoglobulin G4-Related Disease (IgG4-RD) UPLIZNA is indicated for the treatment of Immunoglobulin G4-related disease (IgG4-RD) in adult patients. 1.3 Generalized Myasthenia Gravis (gMG) UPLIZNA is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive.
Mechanism: The mechanism by which inebilizumab-cdon exerts its therapeutic effects in NMOSD, IgG4-RD, and gMG is presumed to involve binding to CD19, a cell surface antigen presents on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, inebilizumab-cdon results in antibody-dependent cellular cytolysis.
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 11, 2025 Supplement 4 · Efficacy LetterLabel
- Apr 3, 2025 Supplement 3 · Efficacy · priority review Breakthrough therapyOrphanLabelMedication GuideLetter
- Jun 11, 2020 Original approval · Type 1 - New Molecular Entity NovelBreakthrough therapyOrphanLetterLabelReview
1 products under this application
- UPLIZNA · INEBILIZUMAB-CDON 100MG/10ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Inebilizumab" as an intervention, any sponsor and status, largest first.
- Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSDPivotal-lookingRecruiting
Massachusetts General HospitalAcademic, hospital or other
NCT07010302 · 540 participants (planned) · Start Sep 1, 2026 · Primary completion Jan 2030
Drug: Rituximab (R); Eculizumab (Soliris®) and 3 more · For: NMOSD
Sites: Boston, Massachusetts; Berlin, Germany · 3 sites in all
- Myasthenia Gravis Inebilizumab TrialPivotal-lookingActive, not recruiting
AmgenAmgen (AMGN)
NCT04524273 · 238 participants · Start Oct 15, 2020 · Primary completion May 28, 2024
Drug: inebilizumab; IV Placebo · For: Myasthenia Gravis
Sites: Orange, California; New Haven, Connecticut; Washington D.C., District of Columbia · 104 sites in all
- N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum DisordersPivotal-lookingCompleted
MedImmune LLCAstraZeneca (AZN)
NCT02200770 · 231 participants · Start Apr 1, 2015 · Primary completion Oct 26, 2018
Drug: Inebilizumab · For: Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
Sites: Birmingham, Alabama; Sacramento, California; San Francisco, California · 98 sites in all
AmgenAmgen (AMGN)
NCT06570798 · 220 participants (planned) · Start Jul 16, 2025 · Primary completion Aug 6, 2028
Drug: Inebilizumab; Blinatumomab · For: Systemic Lupus Erythematosus; Active Refractory Rheumatoid Arthritis
Sites: Scottsdale, Arizona; Aurora, Colorado; Hialeah, Florida · 58 sites in all
- A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Pivotal-lookingCompleted
MedImmune LLCAstraZeneca (AZN)
NCT01453205 · 187 participants · Start Feb 27, 2012 · Primary completion Jul 11, 2016
Drug: MEDI-551 2 mg/kg; Rituximab and 3 more · For: Diffuse Large B-Cell Lymphoma
Sites: Birmingham, Alabama; Burbank, California; Palm Springs, California · 81 sites in all
- A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Pivotal-lookingCompleted
MedImmune LLCAstraZeneca (AZN)
NCT01466153 · 183 participants · Start Feb 7, 2012 · Primary completion Jan 8, 2016
Drug: Rituximab; Bendamustine and 1 more · For: Chronic Lymphocytic Leukemia (CLL)
Sites: Birmingham, Alabama; Burbank, California; La Jolla, California · 54 sites in all
- A Trial of Inebilizumab in Participants With Autoimmune HepatitisPivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07598825 · 180 participants (planned) · Start Dec 18, 2026 · Primary completion Jul 30, 2031
Drug: Inebilizumab; Placebo · For: Autoimmune Hepatitis; AIH
Sites: Little Rock, Arkansas; Rialto, California; Valencia, California · 36 sites in all
- Slow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSDPivotal-lookingNot yet recruiting
Tianjin Medical University General HospitalAcademic, hospital or other
NCT07132398 · 170 participants (planned) · Start Sep 1, 2025 · Primary completion Aug 31, 2027
Drug: Slow-tapering glucocorticoids + Inebilizumab; Rapid-tapering glucocorticoids + Inebilizumab · For: Neuromyelitis Optica (NMO); Neuromyelitis Optica Spectrum Disorders (NMOSD)
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- neuromyelitis optica spectrum disorder130
- off label use76
- headache50
- urinary tract infection44
- fatigue39
- nausea38
- myasthenia gravis37
- pneumonia36
- covid-1932
- pain31
- arthralgia25
- death23
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 21 |
| 2021 | 79 |
| 2022 | 22 |
| 2023 | 50 |
| 2024 | 143 |
| 2025 | 161 |
| 2026 | 382 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Uplizna (Inebilizumab-Cdon)
2024 spending
$15.0M
Beneficiaries
64
100 claims
Per beneficiary
$234,900
$4,668.82 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $4,456,141 |
| 2023 | $12,977,952 |
| 2024 | $15,033,602 |
Part B: Uplizna (Inebilizumab-Cdon) · HCPCS J1823
2024 spending
$52.8M
Beneficiaries
201
610 claims
Per beneficiary
$262,865
2024 ASP limit $478.82 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $13,521,358 |
| 2022 | $27,573,167 |
| 2023 | $38,276,760 |
| 2024 | $52,835,927 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis.
Nowak RJ, Benatar M, Ciafaloni E, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Inebilizumab for Treatment of IgG4-Related Disease.
Stone JH, Khosroshahi A, Zhang W, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Multicenter Study
- Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
Cree BAC, Bennett JL, Kim HJ, et al. · Lancet 2019 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis.
Rindi LV, Zaçe D, Braccialarghe N, et al. · Drug Saf 2024 · Systematic Review, Meta-Analysis
- Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study.
Flanagan EP, Levy M, Katz E, et al. · Mult Scler Relat Disord 2022 · Randomized Controlled Trial
- Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
Cree BAC, Kim HJ, Weinshenker BG, et al. · Lancet Neurol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Viela Bio
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.